The Brighterside of News on MSN
New AI model reveals key genetic, social, and lifestyle factors impacting skin cancer risk
Skin cancer impacts millions of Americans annually, but your chances of getting skin cancer and when it is diagnosed depend ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback